← Deep Dives / September 10, 2026

$ANIP: The Only ACTH Gel Left Standing

Mallinckrodt, the previous owner of the only FDA approved ACTH gel franchise in the United States, filed for bankruptcy. Twice. The drug itself, H.P. Acthar Gel, became so associated with pricing scandal and payer hostility that the commercial infrastructure around it essentially collapsed. ANI Pharmaceuticals watched that happen, acquired Purified Cortrophin Gel, relaunched it at a lower price point with a prefilled syringe, and then quietly built one of the fastest growing rare disease franchises in specialty pharma.

Cortrophin Gel did $117.1 million in revenue in Q2 2026, up 43.5% from $75.9 million in Q2 2025. The product has compounded at roughly 103% annually over three years and contributed approximately $348 million to full year 2025 revenue. There is no branded competitor. The FDA’s existing approval covers 19 indications. Generic substitution is structurally difficult because ACTH is a biologically complex peptide hormone, not a small molecule you can copy cleanly.

The thesis is straightforward. ANI has a monopoly in a segment the market wrote off because one company abused it, and it is now expanding into acute gouty arthritis with a dedicated 90-person sales force that went live in late June 2026. That expansion is not yet in the numbers in any meaningful way. Q3 2026 is the first full quarter where it will be. Management has guided Q4 2026 as the strongest quarter of the year, and the stock sits at roughly $71 against an average analyst price target of $108 to $111.

We think the street is modelling the gout ramp conservatively and that the short interest, which runs at nearly 16% of shares outstanding, creates the conditions for a sharp re rating if Q3 execution is clean. That is the bet. Here is the full picture.

The 60 second version

  • ANI Pharmaceuticals ($ANIP) is a specialty biopharmaceutical company whose lead product, Purified Cortrophin Gel, is the only FDA approved ACTH therapy in the U.S. following the effective commercial collapse of H.P. Acthar Gel under Mallinckrodt.
  • The shift: rare disease ACTH therapy is being rebuilt from near zero commercial infrastructure under a new owner with lower prices, a better delivery form, and a 19-indication label across nephrology, rheumatology, neurology, pulmonology, and now acute gout.
  • The number: Cortrophin Gel revenue grew 43.5% year over year to $117.1 million in Q2 2026, accelerating from $81.5 million in Q1 2026 and $75.9 million in Q2 2025.
  • The catalyst with a date: Q3 2026 earnings, expected around November 6 to 7, 2026, will be the first quarter with a full contribution from the 90-person gout sales force, which went live in late June 2026. SYNCHRONICITY trial full data presentation is expected at a medical conference in Q4 2026 (exact conference not yet confirmed).
  • The main risk: Cortrophin now represents roughly 45% of guided 2026 revenue. If gout reimbursement proves harder to establish than management expects, the H2 ramp stalls, guidance is at risk, and the 15.76% short interest will feel right rather than wrong.
  • Market capitalisation: approximately $1.65 billion as of September 8, 2026.

Here is a number that should stop you. Cortrophin Gel had a three year revenue compound annual growth rate of approximately 103% through 2025. That is not a typo and it is not a small base effect, because by 2025 the product was generating $348 million annually. A drug with no branded competitor just tripled three years in a row.

The reason the stock is at $71 and not much higher is that the market is doing two things simultaneously: pricing in the Cortrophin momentum while discounting the gout expansion as unproven. Short sellers are essentially betting that gout reimbursement fails and the Cortrophin trajectory is already peak. We think they are wrong on timing if not on the risk itself, and Q3 2026 is the quarter that starts to settle the argument.

ANI’s full year 2026 guidance of $1.08 billion to $1.14 billion in revenue implies a meaningful H2 acceleration. Management has been specific: Q4 is guided as the strongest quarter. The gout salesforce ramp is the mechanism. What happens between now and November tells us whether this is a re rating event or a guided miss.

The shift

ACTH therapy spent most of the 2010s as a cautionary tale. H.P. Acthar Gel, under Questcor and then Mallinckrodt, became the poster child for specialty drug pricing excess, at one point exceeding $40,000 per vial. Congressional scrutiny, payer restrictions, and eventually Mallinckrodt’s two trips through bankruptcy court destroyed the commercial ecosystem around the drug. Nephrologists and rheumatologists who had used ACTH for decades stopped writing it because access was a nightmare.

What that created, inadvertently, was an open field. The underlying biology of ACTH is not in dispute. Cortisol stimulation via ACTH has documented clinical utility across nephrotic syndrome, acute exacerbations of multiple sclerosis, rheumatoid arthritis, and several pulmonary indications. Physicians who knew the drug remained interested. They just had no functional commercial alternative.

ANI launched Cortrophin Gel with a price that was meaningfully below legacy Acthar, a prefilled syringe format that simplified administration, and a sales force built specifically around the specialist physicians who already understood ACTH mechanisms. Payers, burned by the Mallinckrodt era, remained skeptical, but the lower list price gave ANI the leverage to renegotiate access over time. The result is a product that has been building prescription volume for three straight years.

The gout indication is the next chapter. Acute gouty arthritis is a painful, episodic condition where corticosteroids are standard of care but ACTH has a well established mechanism and historical use. The FDA label already covers it. ANI does not need a new approval. What it needs is a sales force calling on rheumatologists and podiatrists who treat flares, and a reimbursement pathway that specialty pharmacies can navigate. The 90 reps deployed in late June 2026 are the field infrastructure. Whether the payer infrastructure follows is the open question.

The company

ANI Pharmaceuticals was, for most of its history, a generics focused specialty manufacturer headquartered in Baudette, Minnesota. The Cortrophin Gel acquisition changed the character of the business entirely. Today ANI runs three reportable segments: rare disease (Cortrophin Gel plus the ILUVIEN and YUTIQ ophthalmic implants acquired via the Alimera Sciences deal in September 2024), established brands, and generics. The generics business is deliberately positioned in niche, limited competition products and functions primarily as a cash engine.

Arthur Higgins, who joined as Executive Chairman and then CEO, came out of AbbVie and Bayer. The commercial team around Cortrophin has deep specialty pharma roots. The manufacturing is U.S.-based and proprietary, which matters for ACTH because the purification process for porcine derived ACTH is not something a generic manufacturer can replicate cheaply or quickly.

One detail from the Q2 2026 earnings call that we found notable: management reported that more than 95% of the newly hired gout focused sales representatives opened multiple patient cases within the first few weeks of going live. That is a very specific operational claim and a relatively unusual thing to disclose this early in a launch. It could reflect genuine early physician interest, or it could reflect that the reps are working hard to make an impression in week one. Either way, management chose to say it, which tells you something about how important the gout narrative is to the H2 guidance story.

The numbers and what the street expects

Full year 2025 revenue was $883 million, up 44% year over year. The growth rate actually decelerated modestly in Q1 2026, with total revenue of $237.5 million representing 20.5% growth, before reaccelerating in Q2 2026 to $266 million and 25.9% growth. The rare disease segment specifically grew 30.7% year over year in Q2 2026 to $135.8 million. Within that, Cortrophin alone was $117.1 million, a 43.5% increase and a clear sequential acceleration from $81.5 million in Q1.

Management has guided full year 2026 revenue of $1.08 billion to $1.14 billion, which implies approximately $576 to $637 million in H2 2026 revenue against $503.5 million in H1 actuals. That is a significant step up. The mechanism is the gout ramp, seasonal payer dynamics in Q4, and continued underlying Cortrophin volume growth. Management was explicit that Q4 is guided as the single strongest quarter of the year.

On EBITDA, non GAAP adjusted EBITDA was $71.6 million in Q2 2026, up 32.4% year over year. Full year non GAAP adjusted EBITDA guidance is $285 million to $300 million. Non GAAP diluted EPS guidance is $9.19 to $9.69. The EPS midpoint of $9.44 sits roughly 4 to 5% above the consensus estimate of $9.05 that Seeking Alpha reported as of April 2026. On revenue, guidance midpoint of $1.11 billion is roughly in line with the nine analyst consensus of $1.09 billion per stockanalysis.com.

The gross margin picture deserves attention. Non GAAP gross margin came in at 62.6% in Q2 2026, which was down 230 basis points year over year. Management attributed this to mix shift toward royalty bearing products. Full year guidance is 59.9% to 60.9%. That is a meaningful compression from where the business ran in 2024, and it is the one financial trend that cuts against the operating leverage story. If Cortrophin mix keeps growing but royalty costs scale with it, the margin floor could be lower than the street has modelled.

The balance sheet is in good shape for a company this size. Cash stood at $360.2 million as of June 30, 2026, up from $285.6 million at year end 2025. Operating cash flow was $115 million through the first half of 2026, and the company generated $185.2 million in operating cash flow for full year 2025. There is no quarterly cash burn. Debt outstanding is $620.9 million in principal, including senior convertible notes, but net leverage is approximately 1.0 times trailing EBITDA, which is manageable given the cash generation trajectory. ANI also authorized a $100 million share repurchase program in May 2026, which at the current stock price is not trivial relative to the float.

Dilution has been moderate. Shares outstanding grew from approximately 21.1 million in December 2024 to approximately 23 million now, roughly 9% over 18 months, almost entirely related to the Alimera Sciences acquisition. There is no indication of equity issuance in the near term given the cash position.

Q2 2026 was a beat on both lines. Revenue of $266 million came in above the $260.1 million consensus per MarketBeat. Non GAAP EPS of $2.21 beat the $2.04 consensus. Zacks revised its consensus estimate upward by 7.8% over one month as of April 2026, reflecting the early year guidance raise. For Q3 2026, the implied revenue range from guidance math is roughly $277 to $285 million, though we cannot confirm a specific street consensus from a primary source and treat that range as an approximation.

Why it wins

The moat here is structural and somewhat strange. Cortrophin Gel is protected not primarily by a patent wall but by the wreckage of its predecessor. H.P. Acthar Gel spent a decade being weaponized on pricing and then its owner went bankrupt, twice. Any pharmaceutical company looking at ACTH as a commercial opportunity is looking at that history and deciding the regulatory, political, and payer relations work required to launch a new entrant is not worth it, especially with ANI already occupying the field at a more defensible price point.

The manufacturing complexity adds a layer. Porcine derived ACTH purification is not a commodity process. ANI’s U.S. manufacturing is proprietary. A generic manufacturer would need to build or license that process, invest in an abbreviated new drug application process that is anything but simple for a biologically complex peptide, and then sell at a discount to a product already priced below where Acthar was. The economics do not work cleanly.

The 19-indication label is also a meaningful structural asset. ANI does not need to run a new Phase 3 trial to sell Cortrophin into gout. The FDA label already covers it. Competitors would need to start from clinical data and work through years of development to match that label breadth. ANI is simply deploying a larger field force against indications it is already legally permitted to promote.

The ILUVIEN and YUTIQ assets from Alimera give the company a second rare disease channel in ophthalmology, with the SYNCHRONICITY Phase 4 trial data for ILUVIEN in chronic non infectious uveitis providing a potential label expansion catalyst in the institutional and hospital channel. That is additive, not core, but it represents optionality the market has not fully priced.

What could go wrong

Cortrophin Gel is now approaching 45% of total guided 2026 revenue. That concentration is the central risk, full stop. If the gout expansion does not convert early physician interest into durable prescriptions with reliable reimbursement, ANI misses H2, and the guidance range of $1.08 billion to $1.14 billion becomes a problem rather than a floor.

The specific mechanism of failure worth understanding is the gross to net dynamic in a new indication. Gout is not nephrotic syndrome or MS. The payers have no established reimbursement history for ACTH in acute gout flares. Every new prescription in the gout indication likely requires prior authorization, and specialty pharmacy adjudication in a new indication can be slow and unpredictable. Analysts flagged on the Q2 2026 call that a disconnect existed between IQVIA tracked prescription data and reported Cortrophin revenue, and management did not fully resolve that question on the call. We noted that and consider it an open item going into Q3 reporting.

There is also a macro payer risk. Federal drug pricing pressure, including pharmacy benefit manager reform and potential CMS scrutiny of specialty drug access, could tighten the reimbursement environment for exactly the kind of premium priced ACTH therapy ANI sells. This is a slow moving risk but not a trivial one.

The short interest of roughly 15.76% of shares outstanding is elevated. Short sellers are not wrong about the risks above. If Q3 execution disappoints, the stock does not drift down gently from $71; it moves hard and fast. A 16% short position in a name with 344,000 shares of average daily volume is a concentrated bet that resolves violently in either direction.

Finally, the gross margin compression trend is worth watching as its own story. If royalty bearing product mix continues to grow faster than the core Cortrophin margin profile, the business could deliver revenue beats while the earnings power stays flatter than the top line implies. The market would eventually reprice that dynamic.

The investment thesis

ANI Pharmaceuticals is a rare disease franchise with a structural monopoly in ACTH therapy, trading at roughly 1.5 times 2026 guided revenue and approximately 7.5 times guided EBITDA, at a 35% discount to the average analyst price target, with a catalyst arriving in November.

The market appears to be pricing two things simultaneously: it believes the Cortrophin core business, and it is sceptical of the gout expansion. That scepticism is reasonable on its own terms. What it produces is a valuation that assigns essentially no credit to the gout indication contribution expected in H2 2026, despite management guiding Q4 as the strongest quarter of the year and despite early field data that was specific enough to include the detail that over 95% of new reps opened multiple cases within weeks. The gap between guidance midpoint EPS of $9.44 and the street consensus of $9.05 is partly this expansion being undermodelled.

For the thesis to work, three things need to be true. First, gout reimbursement must flow cleanly enough through specialty pharmacy channels that Q3 revenue reflects meaningful new prescription volume. Second, the underlying Cortrophin trajectory in nephrology, rheumatology, and neurology continues without a stepdown in existing indications. Third, gross margin stabilises in the 60% to 61% range guided rather than continuing to compress. None of these are heroic assumptions, but all three have to hold simultaneously for H2 2026 to print at the guided level.

Q3 2026 earnings, expected around November 6 or 7, is the moment. It is the first clean read on whether the 90-person gout sales force is building durable revenue or just opening cases that are falling through payer adjudication. The SYNCHRONICITY data presentation in Q4 2026 adds a second catalyst that the street has not meaningfully modelled because the conference and date remain unconfirmed.

This is a name to hold through Q3 earnings rather than to chase into the print. The elevated short interest means the setup is either a squeeze or a confirmation, not a quiet drift in either direction.

The single observable that would tell us the thesis is wrong: if Q3 2026 Cortrophin Gel revenue comes in below $120 million, the gout ramp is not materialising at the pace guidance requires, and H2 delivery becomes dependent on a Q4 recovery that would require payer dynamics to shift sharply in one quarter.

What we are watching

  • Q3 2026 earnings release, expected approximately November 6 to 7, 2026: Cortrophin Gel revenue figure and any management disclosure about gout prescription volume versus actuals.
  • October 2026: any IQVIA prescription data for Cortrophin in the gout indication, watched by analysts for the script to revenue alignment question flagged on the Q2 call.
  • Q4 2026 medical conference (date unconfirmed): full SYNCHRONICITY trial data presentation for ILUVIEN in chronic non infectious uveitis, which is the catalyst for the institutional ophthalmology channel.
  • Next short interest update, approximately mid October 2026: whether the 15.76% short interest is increasing or covering ahead of Q3 earnings.
  • Any CMS or PBM policy announcement affecting specialty ACTH reimbursement, which would be a negative surprise with no obvious timing but is worth monitoring given the federal drug pricing environment.

The bottom line

ANI built a rare disease franchise on the ruins of one of specialty pharma’s most visible failures. That is actually how durable moats sometimes get created: not through clever IP strategy but because the previous owner made such a mess that no rational competitor wants to follow them in. Cortrophin Gel has no branded competitor, a 19-indication label, proprietary manufacturing, and three years of accelerating growth. The ACTH market was not broken by science. It was broken by pricing and management, and ANI fixed both.

The gout expansion is the chapter the market has not priced. Ninety new reps, a pre existing FDA label, and a specialist physician base that already understands ACTH are the inputs. Q3 2026 earnings are the output that either validates the H2 story or forces a reset. The 15.76% short interest tells you the bears think a reset is coming. We think they are wrong about timing, and possibly wrong about magnitude, but the risk is real enough that the gross to net question in a brand new indication deserves more disclosure than management has provided so far.

What would change our mind: a Q3 miss driven by gout reimbursement failure, combined with any sign of deceleration in the legacy Cortrophin indications, would indicate that the H2 ramp was always a management ambition rather than a commercial reality. That combination, a gout shortfall plus legacy softness, would be the falsification. Until we see Q3 actuals, the thesis holds.

Not financial advice.

References

  1. Motley Fool. ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript. Published August 14, 2026. Accessed September 10, 2026. https://www.fool.com/earnings/call-transcripts/2026/08/14/ani-pharmaceuticals-anip-q2-2026-earnings-call-transcript/
  2. Yahoo Finance. ANI Pharmaceuticals Inc (ANIP) Q2 2026 Earnings Call Highlights. Published August 7, 2026. Accessed September 10, 2026. https://finance.yahoo.com/healthcare/articles/ani-pharmaceuticals-inc-anip-q2-190135224.html
  3. Quiver Quantitative. ANI Pharmaceuticals Reports Second Quarter 2026 Results. Published August 7, 2026. Accessed September 10, 2026. https://www.quiverquant.com/news/ANI+Pharmaceuticals+Reports+Second-Quarter+2026+Results,+Raises+Cortrophin+Gel+Guidance+and+Reaffirms+Full-Year+Outlook
  4. NewsFilter. ANI Pharmaceuticals Second Quarter 2026 Earnings Summary. Published August 7, 2026. Accessed September 10, 2026. https://newsfilter.io/earnings/ani-pharmaceuticals-second-quarter-2026-earnings-summary-e570bc5ec71ab858a295c8dcc947918f
  5. StockTitan. ANI Pharmaceuticals Q2 Earnings: Revenue $266M, Up 25.9%. Published August 7, 2026. Accessed September 10, 2026. https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-reports-record-second-quarter-2026-financial-b2t0s3xib7g5.html
  6. MarketBeat. ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results. Published August 8, 2026. Accessed September 10, 2026. https://www.marketbeat.com/instant-alerts/ani-pharmaceuticals-nasdaqanip-announces-earnings-results-2026-08-07/
  7. ANI Pharmaceuticals. Form 8-K: Fourth Quarter and Full Year 2025 Results. US Securities and Exchange Commission. Published February 27, 2026. Accessed September 10, 2026. https://investor.anipharmaceuticals.com/news-releases/news-release-details/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-1
  8. ANI Pharmaceuticals. Form 8-K: FY2026 Initial Guidance. US Securities and Exchange Commission. Published February 27, 2026. Accessed September 10, 2026. https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/anip-20260227xexx991.htm
  9. ANI Pharmaceuticals. Corporate Presentation May 2026. Published May 2026. Accessed September 10, 2026. https://investor.anipharmaceuticals.com/static-files/0724a7e7-bcd5-48d7-8645-955d12e282d8
  10. ANI Pharmaceuticals IR. ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial. Published May 22, 2025. Accessed September 10, 2026. https://investor.anipharmaceuticals.com/news-releases/news-release-details/ani-pharmaceuticals-announces-initiation-phase-4-clinical-trial
  11. ChartMill. ANI Pharmaceuticals Q1 2026 Estimates, Raises Full Year Guidance. Published May 8, 2026. Accessed September 10, 2026. https://www.chartmill.com/news/ANIP/Chartmill-48017-ANI-Pharmaceuticals-NASDAQANIP-Crushes-Q1-Estimates-Raises-Full-Year-Guidance
  12. TipRanks. ANIP Stock Analysis. Accessed September 10, 2026. https://www.tipranks.com/stocks/anip
  13. StockAnalysis. ANI Pharmaceuticals (ANIP) Statistics and Valuation. Accessed September 10, 2026. https://stockanalysis.com/stocks/anip/statistics/
  14. StockAnalysis. ANI Pharmaceuticals Forecast and Analyst Price Targets. Accessed September 10, 2026. https://stockanalysis.com/stocks/anip/forecast/
  15. TradingKey. ANIP Institutional Confidence. Published July 30, 2026. Accessed September 10, 2026. https://www.tradingkey.com/markets/stocks/anip/sentiment
  16. Morningstar. ANIP Stock Price Quote. Published September 2, 2026. Accessed September 10, 2026. https://www.morningstar.com/stocks/xnas/anip/quote
  17. WallStreetZen. ANI Pharmaceuticals Stock Price Today. Published September 8, 2026. Accessed September 10, 2026. https://www.wallstreetzen.com/stocks/us/nasdaq/anip
  18. Seeking Alpha. ANIP Earnings Estimates. Published April 2026. Accessed September 10, 2026. https://seekingalpha.com/symbol/ANIP/earnings/estimates
  19. Benzinga. ANIP Short Interest. Published December 2025. Accessed September 10, 2026. https://www.benzinga.com/quote/ANIP/short-interest
  20. Yahoo Finance. ANI Pharmaceuticals Q4 Earnings Call Highlights. Published February 27, 2026. Accessed September 10, 2026. https://finance.yahoo.com/news/ani-pharmaceuticals-q4-earnings-call-152427260.html
  21. Zacks / QZ. ANI Pharmaceuticals 2026 Catalysts Include Gout Push and New Generics. Published April 20, 2026. Accessed September 10, 2026. https://qz.com/ani-pharmaceuticals-2026-catalysts-include-gout-push-and-new-generics
  22. Yahoo Finance / QZ. Can ANI Climb 43.86% to Reach Wall Street Target. Published April 2, 2026. Accessed September 10, 2026. https://qz.com/can-ani-anip-climb-43-86-to-reach-the-level-wall-street-analysts-expect
  23. Simply Wall St. ANI Pharmaceuticals Stock Analysis. Published August 2026. Accessed September 10, 2026. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anip/ani-pharmaceuticals
  24. Yahoo Finance. ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary. Published August 7, 2026. Accessed September 10, 2026. https://finance.yahoo.com/healthcare/articles/ani-pharmaceuticals-inc-q2-2026-212202679.html
  25. Quartr. ANI Pharmaceuticals (ANIP) Investor Relations Summary. Accessed September 10, 2026. https://quartr.com/companies/ani-pharmaceuticals-inc_12958
  26. CNN Markets. ANIP Stock Quote and Forecast. Published July 2026. Accessed September 10, 2026. https://www.cnn.com/markets/stocks/ANIP
Positions and business relationships. Assume that Dr. Paul Christianson and/or Disruptor Investing, LLC may hold a long or short position in any security mentioned above, whether or not a position is stated, and may buy or sell at any time without notice. Assume also that a company mentioned above may be a current or former paid client of Disruptor Investing's CEO interview program, or may otherwise have a business relationship with Disruptor Investing. This research is reviewed before publication but is not a substitute for your own diligence. Verify every figure against the company's SEC filings before relying on it. Nothing here is investment, legal, tax, or financial advice. Dr. Christianson is not a registered financial advisor, investment adviser, or broker-dealer. Educational content only. Full disclosures and compensation terms.
See the membership More Deep Dives